{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:30:52Z","timestamp":1785396652520,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2002,4,1]]},"DOI":"10.1038\/sj.leu.2402439","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:42:14Z","timestamp":1031251334000},"page":"632-635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission"],"prefix":"10.1038","volume":"16","author":[{"given":"R","family":"Oudat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MJ","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Albitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,4,16]]},"reference":[{"key":"BF2402439_CR1","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/sj.leu.2400679","volume":"11","author":"C Rozman","year":"1997","unstructured":"Rozman C, Bosch F, Montserrat E . Chronic lymphocytic leukemia: a changing natural history? Leukemia 1997 11: 775\u2013778","journal-title":"Leukemia"},{"key":"BF2402439_CR2","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.1994.12.9.1974","volume":"12","author":"GB Faguet","year":"1994","unstructured":"Faguet GB . Chronic lymphocytic leukemia: an updated review J Clin Oncol 1994 12: 1974\u20131990","journal-title":"J Clin Oncol"},{"key":"BF2402439_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<208::AID-AJH2>3.0.CO;2-E","volume":"62","author":"N Zengin","year":"1999","unstructured":"Zengin N, Kars A, Sungur A, Zengin NI, Hayran M, Tekuzman G, Kansu E, Ruacan S, Firat D . The significance of bone marrow biopsy pattern in chronic lymphocytic leukemia: a prognostic dilemma Am J Hematol 1999 62: 208\u2013211","journal-title":"Am J Hematol"},{"key":"BF2402439_CR4","first-page":"1094","volume":"84","author":"S Molica","year":"1999","unstructured":"Molica S, Levato D, Dattilo A . Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease-progression on overall survival Haematologica 1999 84: 1094\u20131099","journal-title":"Haematologica"},{"key":"BF2402439_CR5","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V81.11.2878.2878","volume":"81","author":"MJ Keating","year":"1993","unstructured":"Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, Beran M, Freireich EJ . Long term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent Blood 1993 81: 2878\u20132884","journal-title":"Blood"},{"key":"BF2402439_CR6","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood.V82.6.1695.1695","volume":"82","author":"S O'Brien","year":"1993","unstructured":"O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M . Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis derived prognostic model of response to treatment Blood 1993 82: 1695\u20131700","journal-title":"Blood"},{"key":"BF2402439_CR7","first-page":"1444","volume":"9","author":"LE Robertson","year":"1995","unstructured":"Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Plunkett W, Keating MJ . A 3-day schedule of Fludarabine in previously treated chronic lymphocytic leukemia Leukemia 1995 9: 1444\u20131449","journal-title":"Leukemia"},{"key":"BF2402439_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF01714952","volume":"63","author":"W Hiddeman","year":"1991","unstructured":"Hiddeman W, Rottmann R, Wormann B . Treatment of advanced chronic lymphocytic leukemia by fludarabine: results of a clinical phase II study Ann Haematol 1991 63: 1\u20134","journal-title":"Ann Haematol"},{"key":"BF2402439_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3109\/10428199609093445","volume":"21","author":"E Montserrat","year":"1996","unstructured":"Montserrat E, Lopez-Lorenzo JL, Manso F, Martin A, Prieto E, Arias-Sampedro J, Fernandez MN, Oyarzabal FJ, Odrizaba J, Alcala A, Garcia-Conde J, Guardia R, Bosch F . Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia. The Spanish Group experience Leuk Lymphoma 1996 21: 467\u2013472","journal-title":"Leuk Lymphoma"},{"key":"BF2402439_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/oxfordjournals.annonc.a059209","volume":"5","author":"C Pott-Hoeck","year":"1995","unstructured":"Pott-Hoeck C, Hiddemann W . Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemia Ann Oncol 1995 5: 421\u2013433","journal-title":"Ann Oncol"},{"key":"BF2402439_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1023\/A:1006100900082","volume":"16","author":"SA Johnson","year":"1998","unstructured":"Johnson SA, Catovsky D, Child JA, Newland AC, Milligan DW, Janmohamed R . Phase I\/II evaluation of pentostatin (2\u2032-deoxyco formycin) in a five-day schedule for the treatment of relapsed\/refractory B-cell chronic lymphocytic leukemia Invest New Drugs 1998 16: 155\u2013160","journal-title":"Invest New Drugs"},{"key":"BF2402439_CR12","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","volume":"92","author":"MJ Keating","year":"1998","unstructured":"Keating MJ, O'Beran S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H . Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving Fludarabine regimens as initial therapy Blood 1998 92: 1165\u20131171","journal-title":"Blood"},{"key":"BF2402439_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.1991.9.1.44","volume":"9","author":"MJ Keating","year":"1991","unstructured":"Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB . Fludarabine: a new agent with marked cyto-reductive activities in untreated chronic lymphocytic leukemia J Clin Oncol 1991 9: 44\u201349","journal-title":"J Clin Oncol"},{"key":"BF2402439_CR14","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S0140-6736(96)91681-5","volume":"347","author":"S Johnson","year":"1996","unstructured":"Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B, Wyld PJ, Hiddemann W . Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. The French Cooperative Group on CLL Lancet 1996 347: 1432\u20131438","journal-title":"Lancet"},{"key":"BF2402439_CR15","first-page":"2723","volume":"96","author":"T Robak","year":"2000","unstructured":"Robak T, Blonski JZ, Kasznicki M, Blasinska-Morawiec M, Krykowski E, Dmoszynska A, Mrugala-Spiewak H, Skotnicki AB, Nowak W, Konopka L, Ceglarek B, Maj S, Dwilewicz-Trojaczek J, Hellmann A, Urasinski I, Zdziarska B, Kotlarek-Haus S, Potoczek S, Grieb P . Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial Blood 2000 96: 2723\u20132729","journal-title":"Blood"},{"key":"BF2402439_CR16","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","volume":"343","author":"KR Rai","year":"2000","unstructured":"Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA . Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia N Engl J Med 2000 343: 1750\u20131757","journal-title":"N Engl J Med"},{"key":"BF2402439_CR17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V80.1.29.29","volume":"80","author":"LE Robertson","year":"1992","unstructured":"Robertson LE, Huh YO, Butler JJ, Pugh WC, Hirsch-Ginsberg C, Stass S, Kantarjian H, Keating MJ . Response assessment in chronic lymphocytic leukemia treated with fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis Blood 1992 80: 29\u201336","journal-title":"Blood"},{"key":"BF2402439_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/10428199309064278","volume":"11","author":"MJ Keating","year":"1993","unstructured":"Keating MJ, O'Brien S, Robertson L, Huh Y, Kantarjian H, Plunkett W . Chronic lymphocytic leukemia \u2013 correlation of response and survival Leuk Lymphoma 1993 11: 167\u2013175","journal-title":"Leuk Lymphoma"},{"key":"BF2402439_CR19","first-page":"107","volume":"26","author":"MJ Keating","year":"1999","unstructured":"Keating MJ . Chronic lymphocytic leukemia Semin Oncol 1999 26: 107\u2013114","journal-title":"Semin Oncol"},{"key":"BF2402439_CR20","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR . National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment Blood 1996 87: 4990\u20134997","journal-title":"Blood"},{"key":"BF2402439_CR21","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","volume":"19","author":"SM O'Brien","year":"2001","unstructured":"O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M . Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia J Clin Oncol 2001 19: 1414\u20131420","journal-title":"J Clin Oncol"},{"key":"BF2402439_CR22","volume-title":"Histopathology of the Bone Marrow","author":"AM Rywlin","year":"1976","unstructured":"Rywlin AM . Histopathology of the Bone Marrow Boston: Little Brown 1976"},{"key":"BF2402439_CR23","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1182\/blood.V97.7.1929","volume":"97","author":"A Noy","year":"2001","unstructured":"Noy A, Verma R, Glenn M, Maslak P, Rahman ZU, Keenan JR, Weiss M, Filippa D, Zelenetz AD . Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol Blood 2001 97: 1929\u20131936","journal-title":"Blood"},{"key":"BF2402439_CR24","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/sj.leu.2401706","volume":"14","author":"T Pfitzner","year":"2000","unstructured":"Pfitzner T, Engert A, Wittor H, Schinkothe T, Oberhauser F, Schulz H, Diehl V, Barth S . A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia Leukemia 2000 14: 754\u2013766","journal-title":"Leukemia"},{"key":"BF2402439_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/sj.leu.2401669","volume":"14","author":"J Mattsson","year":"2000","unstructured":"Mattsson J, Uzunel M, Remberger M, Ljungman P, Kimby E, Ringden O, Zetterquist H . Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease Leukemia 2000 14: 247\u2013254","journal-title":"Leukemia"},{"key":"BF2402439_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1600-0609.1996.tb01380.x","volume":"57","author":"CH Geisler","year":"1996","unstructured":"Geisler CH, Hou-Jensen K, Jensen OM, Tinggaard-Pedersen N, Hansen MM, Hansen NE, Holm M, Christensen BE, Drivsholm A, Nielsen JB, Thorling K, Andersen E, Larsen JK, Anderson PK . The bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is not an important prognostic factor Eur J Haematol 1996 57: 292\u2013300","journal-title":"Eur J Haematol"},{"key":"BF2402439_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/10428190009057630","volume":"37","author":"MJ Keating","year":"2000","unstructured":"Keating MJ, Smith TL, Lerner S, O'Brien S, Robertson LE, Kantarjian H, Freireich EJ . Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia Leuk Lymphoma 2000 37: 71\u201385","journal-title":"Leuk Lymphoma"},{"key":"BF2402439_CR28","first-page":"606a","volume":"86 (Suppl.\u20091)","author":"MJ Keating","year":"1995","unstructured":"Keating MJ, Lerner S, Kantarjian H, O'Brien S, Estey E, Freireich E . The serum B2-microglobulin (B2M) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL) Blood 1995 86 (Suppl.\u20091): 606a","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2402439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402439","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T21:19:26Z","timestamp":1648761566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2402439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4,1]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,4,1]]}},"alternative-id":["BF2402439"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2402439","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4,1]]},"assertion":[{"value":"4 May 2001","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2001","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2002","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}